Rupert McShane and Michael Browning have been awarded the title of Associate Professor in recognition of their distinction in their field and contributions to the research, teaching and administration of the department.
Associate Professor Rupert McShane:
"I'm incredibly lucky to be involved in the most exciting advance in psychopharmacology in 50 years: the acute antidepressant action of ketamine. The rapidity of relief that it gives to some people who have been depressed for years is astonishing. I’ve had fantastic support and advice from colleagues in the Department and the Trust. This means we’re now in a great position to look at how to use ketamine, and at how it works.
"In the future I would like to see: a big HTA trial to see whether it can maintain improved function for 6 months; a national registry which includes private as well as NHS clinics; acutely suicidal inpatients receiving ketamine treatment; an international conference at Wadham; a new form of relapse prevention psychotherapy being routinely provided through a national platform. And that’s before we get started on my other interest: driving in dementia project…..So not much really!"
Associate Professor Michael Browning:
“It is a privilege to be awarded the title of Associate Professor and an honour to receive this recognition from the University. I’ve been very lucky to be able to work in such a supportive department which has allowed me to develop both my clinical practice, treating patients with resistant depression, and my research program, which uses computational modelling to better understand psychiatric illness and to inform the development of potential new treatments. Oxford is a leading centre for the treatment of mood disorders and research into computational neuroscience, so it is difficult to think of anywhere better to be.
“My hope for the future is that we can develop our clinical services to fully incorporate the research advances which are being made. We need services which incorporate innovative methods of assessment and treatment and which routinely offer patients the possibility of enrolling in trials which test new interventions. Lots of innovations are coming out of Oxford—so this is an ideal location to develop this kind of clinical service.”